Nevro

Nevro Corp. engages in the provision of medical devices. The firm focuses on providing products that improve the quality of life of patients suffering from debilitating chronic pain. It develops and commercializes senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company was founded by Konstantinos Alataris in March 2006 and is headquartered in Redwood City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Nevro reports strong Q4 earnings, eyes market growth opportunities

Nevro's Q4 2022 performance reflects revenue growth, strong trial rates, and market share gains, with expectations for continued growth.
Challenges include pandemic impact, pricing pressure, and questions on clinical benefits quantification and CEO search progress.
Opportunities lie in market share gains, differentiation through HFX iQ System, and engagement with payers for PDN and NSRBP.
Overall, Nevro anticipates gradual growth throughout 2023, with minimal impact expected from new competitors like Medtronic and Abbott.

Nevro surpasses Q1 expectations, poised for sustained growth ahead

Nevro's Q1 performance exceeded expectations, showcasing strong growth and positive market reception. With a focus on disruptive technologies, new product launches, and market expansion, the company is well-positioned for continued success amidst optimistic market dynamics.

Nevro reports solid Q2 results, focuses on market growth strategies

Nevro's Q2 2023 performance showed revenue growth and focus on market penetration, with challenges in sales force turnover and competition.
Strengths lie in expanded PDN coverage, clinical data emphasis, and reimbursement wins, while opportunities include market growth and enhanced sales productivity.
Addressing challenges through realignment efforts and compensation plans, Nevro aims to leverage market opportunities and drive profitability in the coming months.
Guidance considers turnover impact, territory rebuilding, and sustained business through therapy consultants, positioning Nevro for future growth and success.

Nevro excels in Q3 earnings, eyes growth through innovative therapies

Nevro's Q3 performance reflects strong revenue growth and success in the PDN market, driven by innovative SCS therapy solutions.
The company's strategic focus on commercial execution, market penetration, and operational efficiencies positions them for future success.
Challenges include increasing market penetration, balancing margin expansion with operational efficiency, and careful consideration of acquisitions.
Opportunities lie in leveraging low market penetration, enhancing customer engagement, and collaborating with key experts for continued growth.

Nevro reports solid Q4 revenue growth, eyes market expansion

Nevro's Q4 2023 performance reflects revenue growth driven by PDN sales, with positive EBITDA and strategic acquisitions enhancing market positioning.
While challenges in operational profitability persist, Nevro's focus on market penetration, physician engagement, and salesforce effectiveness present growth opportunities.
Analyst inquiries into market dynamics, competition, and product differentiation underscore the need for Nevro to navigate operational challenges and capitalize on growth prospects.

Nevro surpasses Q1 expectations, eyes market expansion and margin growth

Nevro's Q1 2024 performance exceeded guidance, driven by HFX iQ and increased replacement device candidates, with restructuring efforts to generate savings in 2024.
Strengths include FDA clearance for Nevro1 in SI joint fusion, Android compatibility for HFX iQ, and focus on expanding market penetration.
Challenges include U.S. trials decline, COGS pressure anticipated, and ensuring sales reps are up to speed, while opportunities lie in expanding margins and market penetration.
Overall, Nevro's strategic focus on SI joint fusion products and margin expansion positions them for growth in 2025 and beyond.

Nevro faces revenue decline but pursues strategic growth initiatives

Nevro's Q2 performance reflects revenue challenges but maintains a positive adjusted EBITDA amidst market pressures.
The company's strategic focus on diversification, commercial execution, and exploring strategic options highlights a proactive approach to driving growth.
With a strong cash position and ongoing efforts to navigate challenges and capitalize on opportunities, Nevro is poised for future success.

Nevro reports revenue decline in Q3 but advances AI therapy

Nevro faced revenue decline in Q3 2024 but maintained stability and improved cash position.
Strategic actions to enhance commercial execution and product innovation show promise for future growth.
Challenges in revenue and profitability persist, but opportunities in therapy expansion and market diversification exist.
Continued focus on cost management and strategic exploration to drive long-term value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Nevro Corp. engages in the development of medical devices. The firm focuses on providing products that improve the quality of life of patients suffering from debilitating chronic pain. It develops and commercializes the senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company was founded by Konstantinos Alataris in March 2006 and is headquartered in Redwood City, CA.

SENZA-PDN 24-Month Follow-Up Results to be Presented on January 14, 2023 SENZA-NSRBP 24-Month Follow-Up Results to be Presented on January 13, 2023 REDWOOD CITY, Calif. , Dec. 14, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that two abstracts for Painful Diabetic Neuropathy (PDN) and Non-Surgical Back Pain (NSBP) were accepted for podium presentations at the 2023 North American Neuromodulation Society Annual Meeting (NANS 2023), and will be presented during the late-breaking plenary sessions on January 13-14, 2023 in Las Vegas, NV.

Nevro Announces Two Presentations from SENZA-PDN and SENZA-NSRBP Clinical Trials Have Been Accepted for Late-Breaking Abstract Sessions at NANS 2023 Annual Meeting

Nevro (NVRO) reported earnings 30 days ago. What's next for the stock?

Why Is Nevro (NVRO) Up 14.9% Since Last Earnings Report?

Obtained FDA approval for its Senza HFX iQ spinal cord stimulation system in October. Revenue growth was reported at 8% YoY and lifted to $100.5mm on adjusted EBITDA of negative $3.8mm.

Nevro: Recent Developments Corroborate Breakout, Revise To Buy

Investors continue to be optimistic about Nevro (NVRO), owing to its strength in the global SCS market.

Here's Why You Should Hold on to Nevro (NVRO) Stock Now

Nevro's (NVRO) worldwide revenues improved on a year-over-year basis in Q3, partly owing to robust domestic performance.

Nevro (NVRO) Q3 Earnings Beat Estimates, 2022 View Revised

Nevro Corporation (NYSE:NVRO ) Q3 2022 Earnings Conference Call November 2, 2022 4:30 PM ET Company Participants Julie Dewey - Chief Corporate Communications & IR Officer Keith Grossman - Chairman, CEO & President Roderick MacLeod - CFO Conference Call Participants Simran Kaur - Piper Sandler & Co. Joanne Wuensch - Citi Devin Geiman - Nephron Research David Rescott - Truist Securities Brandon Vazquez - William Blair & Company Nathan Treybeck - Wells Fargo Securities Robert Marcus - JPMorgan Chase & Co. David Turkaly - JMP Securities Operator Good afternoon. My name is Erica, and I will be your conference operator today.

Nevro Corporation (NVRO) Q3 2022 Earnings Call Transcript

REDWOOD CITY, Calif. , Nov. 2, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its financial results for the third quarter ended September 30, 2022, narrowed its full-year 2022 guidance and raised its full-year revenue contribution from painful diabetic neuropathy (PDN).

Nevro Reports Third Quarter 2022 Financial Results, Narrows Full-Year 2022 Guidance and Raises Revenue Contribution from Painful Diabetic Neuropathy

ABIOMED

Glaukos

Masimo

Let us take a look at some MedTech stocks, NVRO, MASI, ABMD and GKOS, which are poised to beat on third-quarter earnings.

4 MedTech Stocks Set to Outpace Q3 Earnings Estimates

Nevro (NVRO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Nevro (NVRO) Expected to Beat Earnings Estimates: Should You Buy?

Nevro (NVRO) gets FDA approval for its next-generation SCS system, Senza HFX iQ, for treating chronic back and leg pain.

Nevro (NVRO) Gains Following FDA Approval for Senza HFX iQ

Next Generation Senza® HFX iQ™ is the First and Only SCS System that Uses Artificial Intelligence to Optimize and Maintain Pain Relief Using Each Patient's Response REDWOOD CITY, Calif. , Oct. 12, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for the Senza HFX iQ spinal cord stimulation (SCS) system.

Nevro Announces FDA Approval of HFX iQ™ Spinal Cord Stimulation System to Personalize the Treatment of Chronic Pain

REDWOOD CITY, Calif. , Oct. 10, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that on October 1, 2022, UnitedHealthcare ("United") released an update to its medical coverage policy (number 2022T0567V) and added language to indicate spinal cord stimulation (SCS) devices are not covered for treating chronic intractable back pain without prior spine surgery (NSBP).

Nevro Comments on UnitedHealthcare Medical Coverage Policy Update

Company to Host Conference Call on Wednesday, November 2, 2022 at 1:30 pm PT / 4:30 pm ET REDWOOD CITY, Calif. , Oct. 5, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that the company will report its financial results for the third quarter ended September 30, 2022 after the market closes on November 2, 2022.

Nevro to Report Third Quarter 2022 Financial Results

REDWOOD CITY, Calif. , Oct. 4, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced today that the U.S. Food and Drug Administration (FDA) has approved its manufacturing operations in Costa Rica for the production of its proprietary spinal cord stimulation systems for the treatment of chronic pain, including its HFX product platform.

Nevro Announces FDA Approval of Costa Rica Manufacturing Operations

REDWOOD CITY, Calif. , Oct. 3, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that Nevro's HFX 10 kHz Therapy is the only form of spinal cord stimulation (SCS) therapy to be referenced by the American Association of Clinical Endocrinology (AACE) in its 2022 Diabetes Clinical Practice Guideline to treat painful diabetic neuropathy (PDN).

Nevro Announces American Association of Clinical Endocrinology Clinical Practice Guideline Has Been Updated to Include High-Frequency 10 kHz Spinal Cord Stimulation to Treat Painful Diabetic Neuropathy

Why Is Nevro (NVRO) Down 1% Since Last Earnings Report?

Latest favorable coverage decisions for Nevro's (NVRO) PDN Therapy are expected to serve a wider patient pool.

Nevro's (NVRO) PDN Therapy Gets Positive Coverage Updates

Aetna Updates Spinal Cord Stimulation Coverage Policy to Include Painful Diabetic Neuropathy Effective Immediately Medicare Administrative Carriers Novitas and First Coast Propose Positive Local Coverage Determinations REDWOOD CITY, Calif. , Sept. 1, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that Aetna has updated their spinal cord stimulation (SCS) coverage policy to explicitly cover painful diabetic neuropathy (PDN), effective August 29, 2022.

Nevro Announces Multiple Positive Coverage Updates for the Treatment of Painful Diabetic Neuropathy

Here's Why You Should Hold on to Nevro (NVRO) Stock for Now

REDWOOD CITY, Calif. , Aug. 9, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced today that it is participating in the following investor conferences: On September 9, 2022, Rod MacLeod, Chief Financial Officer, will present at the Wells Fargo Healthcare Conference at 9:10 am Eastern Time at the Encore Boston Harbor Hotel in Boston, MA.

Nevro Announces Participation In Upcoming Investor Conferences

Nevro Corp. (NYSE:NVRO ) Q2 2022 Earnings Conference Call August 3, 2022 4:30 PM ET Company Participants Julie Dewey - Corporate Communications & IR Officer Keith Grossman - Chairman, President & CEO Roderick MacLeod - CFO Conference Call Participants Larry Biegelsen - Wells Fargo Calvin Chu - Morgan Stanley Simran Kaur - Piper Sandler Robert Marcus - JPMorgan Anthony Occhiogrosso - Citi David Rescott - Truist Securities Margarate Boeye - William Blair Operator Good afternoon. My name is David, and I'll be your conference operator today.

Nevro Corp. (NVRO) CEO Keith Grossman on Q2 2022 Results - Earnings Call Transcript

Nevro's (NVRO) worldwide revenues improve on a year-over-year basis in Q2, partly owing to robust domestic performance.

Nevro (NVRO) Q2 Earnings Beat Estimates, FY22 View Revised

REDWOOD CITY, Calif. , Aug. 3, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its financial results for the second quarter ended June 30, 2022, provided guidance for the third quarter of 2022 and updated its full-year 2022 guidance.

Nevro Reports Second Quarter 2022 Financial Results, Provides Third Quarter 2022 Guidance and Updates Full-Year 2022 Guidance

Boston Scientific

Parties Reach an Agreement that Concludes Outstanding Intellectual Property Disputes REDWOOD CITY, Calif. , Aug. 1, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO) and Boston Scientific Corp. (NYSE: BSX) announced today that they have reached a settlement in their ongoing intellectual property litigations that gives Boston Scientific the freedom to operate using the features and capabilities embodied in its current line of products for frequencies below 1,500 Hz, and gives Nevro the freedom to operate using the features and capabilities embodied in its current line of products.

Nevro and Boston Scientific Announce the Settlement of Their Ongoing Intellectual Property Litigations

Wednesday, August 10, 2022 at 2:30 pm Eastern Time REDWOOD CITY, Calif. , July 21, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that Rod MacLeod, Nevro's Chief Financial Officer, will present at the Canaccord Genuity 42nd Annual Growth Conference on Wednesday, August 10, 2022 at 2:30 pm Eastern Time at the InterContinental Boston Hotel in Boston, MA.

News for Nevro Stock (NVRO)